Well Referenced

Tag: Doxorubicin

Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients

This 2022 randomized, double-blind, placebo-controlled trial investigated the effects of alpha-lipoic acid (ALA) in reducing chemotherapy-induced toxicities in 64 women with breast cancer undergoing treatment with doxorubicin, cyclophosphamide, and paclitaxel. Patients were assigned to receive either ALA (600 mg/day) or placebo for six months. ALA significantly improved chemotherapy-induced peripheral neuropathy

Read More »
June 26, 2025 No Comments

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro

This study investigates the synergistic effect of ascorbic acid (vitamin C) on the antineoplastic activity of common chemotherapy agents—doxorubicin, cisplatin, and paclitaxel—against human breast carcinoma cells. The findings demonstrate that ascorbic acid enhances the efficacy of these chemotherapeutic agents by improving their cytotoxic effects. This suggests that vitamin C could

Read More »
June 26, 2025 No Comments